靶向阻断COX-2信号通路对喉癌细胞生长的影响 |
| |
引用本文: | 王巍毅,李仕晟,杨新明,肖旭平. 靶向阻断COX-2信号通路对喉癌细胞生长的影响[J]. 中国耳鼻咽喉颅底外科杂志, 2010, 0(6): 419-423 |
| |
作者姓名: | 王巍毅 李仕晟 杨新明 肖旭平 |
| |
作者单位: | [1]湖南省人民医院耳鼻喉头颈外科,湖南长沙410002 [2]中南大学湘雅二医院耳鼻咽喉头颈外科,湖南长沙410011 |
| |
摘 要: | 目的观察赛来昔布靶向阻断COX-2信号通路对喉癌细胞生长的影响。方法用不同浓度的赛来昔布处理喉癌细胞Hep-2,通过MTT法检测赛来昔布对喉癌细胞的生长抑制率的影响。用浓度为15μmol/L的赛来昔布处理Hep-2细胞,通过流式细胞学检测药物处理前后细胞周期、凋亡率的差异,运用Western blot检测药物处理前后相关蛋白EGFR和COX-2表达的差异。结果赛来昔布处理后的Hep-2细胞与药物浓度成比例地出现生长抑制率增高;赛来昔布干预组细胞G1期比例大于对照组(P〈0.01),凋亡率明显升高(P〈0.05);与对照组相比,赛来昔布干预组出现明显的p-EGFR,COX-2表达降低(P〈0.05)。结论赛来昔布能抑制喉癌细胞株Hep-2生长,增加Hep-2细胞G1期阻滞,降低肿瘤细胞增殖能力和诱导细胞凋亡;赛来昔布可抑制喉癌细胞COX-2的表达和EGFR的磷酸化。提示COX-2抑制剂可能作为喉癌靶向治疗的新方法。
|
关 键 词: | 喉肿瘤,癌 赛来昔布 环氧合酶-2 表皮生长因子受体 靶向治疗 |
Effects of target blocking COX-2 on the growth of laryngeal cancer |
| |
Affiliation: | WANG Wei-yi,LI Shi-sheng,YANG Xin-ming,et al.(Department of Otorhinolaryngology-Head and Neck Surgery,Hunan Provincial People’s Hospital,Changsha 410002,China) |
| |
Abstract: | Objective To explore the effect of COX-2 inhibitor(Celecoxib) on laryngeal cancer cell lines Hep-2.Methods Laryngeal cancer cell lines Hep-2 was treated with Celecoxib at various concentrations.Cell growth inhibition rate was measured by MTT.After Hep-2 cells were treated with Celecoxib at the concentration of 15 μmol/L,the cell cycle and apoptosis of the cells were measured by flow cytometric analysis.The expression of relative proteins was also examined using western blot.Results ① The cell growth inhibition rate of Celecoxib-treated group was much higher than that of the control,and the inhibition was concentration-dependent in a certain range.② The G1 ratio and apoptotic rate of Celecoxib-treated group were significantly higher than those of the control group respectively(P0.05).③ Compared with the control group,the expression of p-EGFR and COX-2 in Celecoxib-treated group decreased significantly(P0.05).Conclusion Celecoxib can inhibit the growth and induce apoptosis of Hep-2 cell lines via significant induction of Hep-2 cells G1.Meanwhile,Celecoxib can reduce phosphorylation of EGFR and expression of COX-2.Therefore,Celecoxib,as a COX-2 inhibitor,may be a new agent for targeting therapy of laryngeal cancer. |
| |
Keywords: | Laryngeal neoplasm carcinoma Celecoxib COX-2 EGFR Targeting therapy |
本文献已被 维普 等数据库收录! |
|